Subscribe

Snapshot

DOI:

An expert review on managing cardiovascular masses using transcatheter vacuum-assisted aspiration; revascularisation vs medical therapy in 3-vessel disease; CT-μFR; follow-up after mitral transcatheter edge-to-edge repair; design of the DAPT-SHOCK-AMI trial; and more

From the aspiration of cardiovascular masses to new techniques for evaluating coronary lesions, or anatomical changes after mitral valve edge-to edge repair, a wide variety of topics are touched on in this issue – but what about that gorilla hiding in your cath lab? Do you know what that could be?

Transcatheter vacuum-assisted aspiration has become an alternative to surgery for certain high-risk patients with intracardiac and intravascular masses of various aetiologies, often seen as thrombi, tumours, or vegetations. In an expert review, Laura Besola, Andrea Colli and colleagues go over the current clinical evidence, indications and the different uses of vacuum-assisted aspiration in the treatment.

In a post hoc analysis of the ISCHEMIA trial, Sripal Bangalore, Judith S. Hochman and colleagues evaluate the outcomes of revascularisation versus medical therapy in patients with three-vessel coronary artery disease. Revascularisation, including both percutaneous coronary intervention and coronary artery bypass grafting, was associated with lower rates of cardiovascular death and myocardial infarction at four years, as well as an improved quality of life.

Tingwen Weng, Shengxian Tu and colleagues investigate the diagnostic performance of the Murray law-based quantitative flow ratio (CT-μFR), which is a novel coronary computed tomography angiography-derived method for quickly computing fractional flow reserve and identifying haemodynamically significant coronary stenoses and lesions.

Using transoesophageal echocardiography (TOE), Joanna Bartkowiak, Fabien Praz and colleagues evaluate anatomical changes and structural complications after mitral transcatheter edge-to-edge repair, investigating their association with clinical outcomes at two years.

Describing the upcoming DAPT-SHOCK-AMI trial, Zuzana Motovska, Deepak L. Bhatt and colleagues discuss the rationale and design of this study, which will randomise more than 500 patients to evaluate the benefits of cangrelor vs crushed ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock.

Volume 20 Number 20
Oct 21, 2024
Volume 20 Number 20
View full issue

Trending articles
69.996

10.4244/EIJV13I12A217 Dec 8, 2017
Swimming against the tide: insights from the ORBITA trial
Al-Lamee R and Francis D
free
59.65

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
57.6

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
38.75

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
15.85

State-of-the-Art

10.4244/EIJ-D-23-01050 Jul 15, 2024
Durability of transcatheter aortic valve implantation
Ternacle J et al
free
Chat with Cory
Hello , I'm Cory and I will do my best to answer your questions about this article. Please remember that this is an experimental feature, and that I'm still learning.
1 What were the key findings of the post-hoc analysis of the ISCHEMIA trial regarding the outcomes of revascularization versus medical therapy in patients with 3-vessel coronary artery disease?
2 How does the novel CT-μFR method perform in identifying hemodynamically significant coronary stenoses and lesions?
3 What anatomical changes and structural complications were observed after mitral transcatheter edge-to-edge repair using transesophageal echocardiography, and how were they associated with clinical outcomes?
4 What is the rationale and design of the upcoming DAPT-SHOCK-AMI trial?
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved